Top 15 Big Pharma CEO Pay

(From Fierce Pharma) - Totally worth checking out the source.
1. Miles White - Abbott - $33.4M
2. Fred Hassan - Schering-Plough - $30.1M
3. Bill Weldon - Johnson & Johnson - $25.1M
4. Bob Essner - Wyeth - $24.1M
5. Robert Parkinson - Baxter - $17.6M
6. Daniel Vasella - Novartis - $15.5M
7. Richard Clark - Merck - $14.5M
8. Frank [...]

Guide to Financial Statements: Intro

The Basics
One of the first things you should do if you want to get into the business side of biotechnology is familiarize yourself with financial statements and basic accounting. Luckily, a degree in accounting or finance is not a prerequisite. There are no nested, partial-differential equations or partition functions involved, and in fact, [...]

Guide to Financial Statements: Balance Sheets

Balance Sheets
A balance sheet is comprised of detailed information about a company’s:

Assets: Things a company owns that have value (can be sold or used to make products that can be sold). This includes, manufacturing plants, equipment, inventory, cash and, importantly for biotech, intellectual property in the form of patent and trademarks.
Liabilities: Things a company [...]

Guide to Financial Statements: Income Statements

An income statement (or profit and loss / P&L) is the report that shows you how much revenue (sales) the company earned in a year and also shows the costs related to obtaining that revenue. Basically, the top line of the income statement has value of total sales while the bottom line is the [...]

Guide to Financial Statements: Cash Flows

Overview
Cash flow statements report a company’s inflows and outflows of cash. This is important for obvious reasons. Cash flow statements basically reorder the income and balance sheets to generate a dynamic movie of changes in cash over time. 
The bottom line of the cash flow statement shows the net increase or decrease in cash [...]

FDA Likes Promacta

A few days ago, I scratched my head in amusement over GSK / Ligand’s decision to submit and NDA based on non-statistically significant results for their thrombocytopenia drug, Promacta.
Well, the scientific advisory committee (after lambasting the drug on Wednesday) unanimously voted in favor of the drug today.
Sometimes, I’m pretty sure I’ll never understand the regulatory [...]

Biopharma Closing Bell: 5.30.08

Top Movers

Gainers (% price change)
Last Trade
Change
Mkt Cap

Ligand Pharmaceuticals
LGND
3.51
+1.16 (49.36%)
333.16M

The Aristotle Corporation
ARTL
10.86
+2.21 (25.55%)
195.07M

ChemGenex Pharmaceuticals
CXSP
18.25
+2.22 (13.81%)
226.12M

Bio-Imaging Tech, Inc.
BITI
8.15
+0.86 (11.80%)
116.16M

Protalix BioTherapeutics
PLX
3.50
+0.34 (10.76%)
265.59M

Losers (% price change)
 

Medical Action Industries
MDCI
13.28
-3.67 (-21.65%)
212.75M

Javelin Pharmaceuticals
JAV
2.82
-0.32 (-10.19%)
138.45M

NxStage Medical, Inc.
NXTM
4.85
-0.54 (-10.02%)
178.45M

Trubion Pharmaceuticals,
TRBN
6.22
-0.52 (-7.72%)
111.04M

Given Imaging Ltd.
GIVN
15.00
-1.23 (-7.58%)
438.79M

Most Actives (dollar volume)
 

Intuitive Surgical, Inc.
ISRG
293.59
+2.12 (0.73%)
11.36B

Pfizer Inc.
PFE
19.38
-0.02 (-0.10%)
131.11B

Johnson & Johnson
JNJ
66.76
+0.34 (0.51%)
188.14B

Merck & Co., Inc.
MRK
38.96
+0.04 (0.10%)
83.63B

Amgen, Inc.
AMGN
44.03
+0.61 (1.40%)
47.94B

Share and Enjoy:

Best Email Title Ever From FDA: Contaminated Nipple Cream

I get these automated emails from the FDA about product recalls. They are all usually pretty benign. They most often entail some undeclared ingredient that was detected in a product you’ve never heard of.
This email was different.
Subject Line: Contaminated Nipple Cream
Body: FDA is warning nursing mothers not to buy or use [...]

Biopharm Closing Bell: 5.29.08

Top Movers

Gainers (% price change)
Last Trade
Change
Mkt Cap

Kosan Biosciences Inc.
KOSN
5.43
+3.78 (229.09%)
231.62M

Poniard Pharmaceuticals,
PARD
4.00
+0.47 (13.31%)
138.75M

GPC Biotech AG (ADR)
GPCB
4.08
+0.46 (12.61%)
150.17M

Telik, Inc.
TELK
2.21
+0.21 (10.50%)
117.48M

Stereotaxis, Inc.
STXS
5.49
+0.52 (10.46%)
204.18M

Losers (% price change)
 

VIVUS, Inc.
VVUS
6.57
-0.79 (-10.73%)
398.09M

Sangamo Biosciences, Inc.
SGMO
11.04
-1.29 (-10.46%)
450.60M

HealthTronics Inc.
HTRN
3.70
-0.33 (-8.19%)
141.42M

Sucampo Pharmaceuticals,
SCMP
11.24
-0.70 (-5.86%)
469.09M

Orthovita, Inc.
VITA
2.28
-0.12 (-5.00%)
172.91M

Most Actives (dollar volume)
 

Johnson & Johnson
JNJ
66.42
+1.54 (2.37%)
187.18B

Pfizer Inc.
PFE
19.40
+0.10 (0.52%)
131.24B

Merck & Co., Inc.
MRK
38.92
+0.26 (0.67%)
83.54B

Abbott Laboratories
ABT
55.96
+1.86 (3.44%)
86.36B

Amgen, Inc.
AMGN
43.42
+0.60 (1.40%)
47.27B

Share and Enjoy:

BMS Acquires Kosan Biosciences for 233% Premium

Rumors about BMS being acquired by a larger drug maker have been floating around for some time now but today, BMS gets to play the big pocketbook.
BMS and Kosan announced that they have signed a merger agreement for $5.50 per share (a 233% premium over Kosan’s previous day [...]

Top Selling Drugs for 2007

Most people are into lists and I am no exception. So, without further ado, here is a list of the top 20 drugs by 2007 sales.
Also, because I’m a nice guy, I’ve published the top 82 compounds with loads of other information that wouldn’t fit in the post (e.g.; 2005 and 2006 sales, CAGR [...]

Biopharm Closing Bell: 5.28.08

Top Movers

Gainers (% price change)
Last Trade
Change
Mkt Cap

Uluru Inc.
ULU
2.00
+0.25 (14.29%)
124.93M

Cytori Therapeutics Inc.
CYTX
7.20
+0.58 (8.76%)
187.95M

Rochester Medical Corp.
ROCM
12.76
+0.97 (8.23%)
150.85M

Cardica, Inc.
CRDC
7.18
+0.53 (7.97%)
112.77M

Inverness Medical
IMA
34.86
+2.40 (7.39%)
2.70B

Losers (% price change)
 

Ligand Pharmaceuticals
LGND
2.30
-1.29 (-35.93%)
218.31M

The Medicines Company
MDCO
18.47
-1.47 (-7.37%)
960.57M

AVANT Immunotherapeutics,
AVAN
12.90
-1.01 (-7.26%)
192.56M

BioCryst Pharmaceuticals,
BCRX
2.77
-0.21 (-7.05%)
105.49M

Hanger Orthopedic Group,
HGR
12.88
-0.85 (-6.19%)
295.67M

Most Actives (dollar volume)
 

Johnson & Johnson
JNJ
64.88
-0.27 (-0.41%)
182.84B

Pfizer Inc.
PFE
19.30
-0.03 (-0.16%)
130.57B

Wyeth
WYE
44.15
+0.96 (2.22%)
58.87B

Merck & Co., Inc.
MRK
38.66
+0.04 (0.10%)
82.98B

Amgen, Inc.
AMGN
42.82
-0.22 (-0.51%)
46.62B

Share and Enjoy:

GSK submits non-statistically significant NDA for Promacta

An FDA reviewer said that Promacta, an experimental platelet-boosting drug seeking an indication for acute treatment of chronic idiopathic thrombocytopenia purpura from GSK, did not help control bleeding any better than a placebo. The reviewer wrote:
“The data provided in this NDA (new drug application) do not demonstrate statistically significant, robust … treatment effect in decreasing [...]

Biopharm Closing Bell: 5.26.08

Top Movers

Gainers (% price change)
Last Trade
Change
Mkt Cap

ChemGenex Pharmaceuticals
CXSP
16.99
+2.00 (13.34%)
210.50M

Trubion Pharmaceuticals,
TRBN
6.63
+0.61 (10.13%)
118.36M

Electro-Optical Sciences,
MELA
8.52
+0.75 (9.65%)
131.22M

SenoRx, Inc.
SENO
7.19
+0.63 (9.60%)
123.74M

Progenics
PGNX
15.35
+1.20 (8.48%)
460.84M

Losers (% price change)
 

GPC Biotech AG (ADR)
GPCB
3.60
-0.73 (-16.86%)
132.61M

Pediatrix Medical Group,
PDX
50.28
-5.15 (-9.29%)
2.37B

Marshall Edwards, Inc.
MSHL
2.83
-0.27 (-8.71%)
194.86M

Verenium Corporation
VRNM
2.39
-0.17 (-6.64%)
152.12M

Alkermes, Inc.
ALKS
11.95
-0.80 (-6.27%)
1.20B

Most Actives (dollar volume)
 

Pfizer Inc.
PFE
19.33
-0.20 (-1.02%)
130.77B

Merck & Co., Inc.
MRK
38.62
-0.12 (-0.31%)
82.90B

Johnson & Johnson
JNJ
65.15
+0.23 (0.35%)
183.61B

Wyeth
WYE
43.19
+0.21 (0.49%)
57.59B

Amgen, Inc.
AMGN
43.04
+0.66 (1.56%)
46.86B

Share and Enjoy:

Alnylam and Takeda Form Alliance In RNAi

I’ll admit, I’m an RNAi hater, but more on that later. Alnylam and Takeda announced today that they have formed an alliance in RNAi therapeutics covering the fields of oncology and metabolic disease. Here are the deal details:

Takeda becomes Alnylam’s strategic partner for RNAi therapeutics over a five-year period
$150M in upfront and near [...]